WiseGuyReports.com adds “Pre-Eclampsia - Pipeline Review, H1 2016” new report to its research database.

PUNE, INDIA, May 4, 2016 /EINPresswire.com/ -- The report “Pre-Eclampsia - Pipeline Review, H1 2016” provides comprehensive information on the therapeutics under development for Pre-Eclampsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pre-Eclampsia and features dormant and discontinued projects.

Complete Report Details Available at https://www.wiseguyreports.com/reports/pre-eclampsia-pipeline-review-h1-2016 .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Inquire more about this report at https://www.wiseguyreports.com/enquiry/pre-eclampsia-pipeline-review-h1-2016 .

Pre-Eclampsia - Companies Involved in Therapeutics Development:
A1M Pharma AB
Alnylam Pharmaceuticals, Inc.
Glenveigh Medical, LLC
Pluristem Therapeutics Inc.
rEVO Biologics, Inc.
RTI International
VG Life Sciences, Inc.

Featured News & Press Releases
Jan 14, 2016: St. John Hospital Enrolling Patients in Phase 3 Trial for Early Onset Preeclampsia
Jan 06, 2016: New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells
Dec 31, 2015: U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem’s PLX-PAD Cells for Treatment of Severe Preeclampsia
Sep 24, 2015: New clinical trial at SLU treats preeclampsia in second-trimester pregnancies
Sep 12, 2014: Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen for the Treatment of Hypertensive Disorders of Pregnancy, Including Preeclampsia
Sep 10, 2014: Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting
Jul 23, 2014: rEVO Biologics Announces Enrollment of First Patient in Phase 3 Trial of ATryn to Treat Early Onset Preeclampsia (PRESERVE-1)
Jul 08, 2014: Orphan Drug Designation Granted in Europe for A1M Pharma’s Treatment for Preeclampsia
Mar 31, 2014: rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial for ATryn in Early-Onset Preeclampsia
Feb 25, 2014: rEVO Biologics Announces the Submission of an IND for ATryn in Preeclampsia

Get a sample copy at https://www.wiseguyreports.com/sample-request/pre-eclampsia-pipeline-review-h1-2016 .

Scope
- The report provides a snapshot of the global therapeutic landscape of Pre-Eclampsia
- The report reviews pipeline therapeutics for Pre-Eclampsia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pre-Eclampsia therapeutics and enlists all their major and minor projects
- The report assesses Pre-Eclampsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pre-Eclampsia

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pre-Eclampsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pre-Eclampsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a Purchase Report Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=443174 .

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here